Tectonic Therapeutic (TECX) to Release Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) is projected to release its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Tectonic Therapeutic to post earnings of ($1.11) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 3:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX) last issued its earnings results on Thursday, February 26th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.08. On average, analysts expect Tectonic Therapeutic to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Tectonic Therapeutic Price Performance

NASDAQ TECX opened at $34.79 on Thursday. The firm’s fifty day moving average price is $22.57 and its 200 day moving average price is $19.96. Tectonic Therapeutic has a 12 month low of $13.70 and a 12 month high of $36.03. The company has a market capitalization of $653.36 million, a price-to-earnings ratio of -8.59 and a beta of 3.76.

Insider Buying and Selling

In other news, CFO Daniel Lochner bought 6,000 shares of the firm’s stock in a transaction on Tuesday, February 10th. The shares were bought at an average cost of $21.61 per share, for a total transaction of $129,660.00. Following the completion of the transaction, the chief financial officer owned 32,044 shares in the company, valued at $692,470.84. This trade represents a 23.04% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Peter Mcnamara sold 6,262 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $30.17, for a total value of $188,924.54. Following the completion of the sale, the insider directly owned 55,285 shares in the company, valued at $1,667,948.45. This trade represents a 10.17% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 19,561 shares of company stock valued at $566,551. Corporate insiders own 38.00% of the company’s stock.

Hedge Funds Weigh In On Tectonic Therapeutic

Institutional investors have recently made changes to their positions in the stock. Orbimed Advisors LLC purchased a new stake in shares of Tectonic Therapeutic in the fourth quarter valued at $11,986,000. Vestal Point Capital LP purchased a new stake in Tectonic Therapeutic during the 4th quarter worth about $6,842,000. Opaleye Management Inc. acquired a new position in Tectonic Therapeutic in the 4th quarter valued at about $4,480,000. Millennium Management LLC lifted its holdings in Tectonic Therapeutic by 726.4% in the 1st quarter. Millennium Management LLC now owns 237,938 shares of the company’s stock valued at $4,214,000 after purchasing an additional 209,145 shares in the last quarter. Finally, Kennedy Capital Management LLC purchased a new position in Tectonic Therapeutic in the 3rd quarter valued at about $3,276,000. 62.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on TECX. Lifesci Capital raised Tectonic Therapeutic to a “strong-buy” rating in a report on Thursday, February 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tectonic Therapeutic in a research report on Thursday, January 22nd. Finally, Truist Financial dropped their price objective on shares of Tectonic Therapeutic from $64.00 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Tectonic Therapeutic has a consensus rating of “Moderate Buy” and an average target price of $81.50.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.